In Japan, a regulation reform will be implemented in November 2014 in the area of regenerative medicine. Companies will be given conditional marketing approval after Phase II trials on the basis that products are proved to be safe and effective to use. Detailed regulatory process and conditions are under discussion and to be announced in due course, and this will give an accelerated path to market entry not only in Japan but also globally.
The Science & Innovation Japan Team organised a “Symposium for Innovation in Regenerative Medicine” in January 2014, inviting regulators, scientists and companies from both the UK and Japan. In order to deepen and extend the discussion to real commercialisation, UKTI and the Science & Innovation Team are planning to organise another symposium in January 2015 in cooperation with Takeda Science Foundation and CiRA Kyoto University (Centre for iPS Cell Research & Application). The eligible UK companies will be provided a product/technology showcasing opportunity at a speaking slot in the seminar programme.